Aerosolized colistin in the treatment of multiresistant Pseudomonas aeruginosa nosocomial pneumonia 

Introduction. Multiresistant Pseudomonas aeruginosa (MRPA) nosocomial pneumonia is a significant cause of mortality and morbidity in the ICU. We report our experience with aerosolized colistin in the treatment of MRPA nosocomial pneumonia. Patients and methods. It is a prospective, observational study performed over 2 years (2006-2007). Patients who develo-ped MRPA nosocomial pneumonia and were treated with aerosolized colistin were included. The criteria used to assess if treatment was successful were extubation and ICU mortality rates.  

Results. We report 32 patients of whom 12 were women and 20 men. The mean age was 48 ± 19 years. All patients were receiving mechanical ventilation. The mean length of ventilation was 22 ± 5.5 days. The bronchial sampling technique used was broncho-alveolar lavage. The mean delay of infection (duration between intubation and pneumonia diagnosis) was 7 ± 2 days. Isolated MRPA was susceptible only to colistin. The treatment was aerosolized colistin for all patients (4 MUI/day). A positive blood culture (n=5) was a prerequisite for administering colistin intravenously (4 MUI/day). Any potential toxicity was observed. The mean delay of extubation after starting treatment was 10 days. Sterile samples were obtained on average by the eighth day. No deaths were recorded.

Conclusion. It seems that aerosolized colistin is an important alternative to treat MRPA nosocomial pneumonia in ICU. Our results need further confirmation by other multicentre studies.

multi-resistant Pseudo-monas aeruginosa, colistin, nebuli-zation, ICU

1. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pne-umonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005,9:53-59.

2. Bellomo R, Ronco C, Kellum JA, Mehta RL, Paul Palevsky. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:204-12.

3. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelpoulos S, Falagas ME. Colistin treatment in patients with ICU acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21.

4. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to anti-microbial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:154-60.

5. Pino G, Conterno G, Colongo PG. Clinical observations on the activity of aerosol colimycin and of endobronchial instillations of colimycin in patients with pulmonary suppurations. Minerva Med 1963;54:2117-22.

6. Marschke G, Sarauw A. Polymyxin inhalation therapeutic hazard. Ann Intern Med 1971;74:144-5.

7. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infec-tions from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-8.

8. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in Intensive Care Unit Patients. Surg infect 2008;9:153-60.